Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by weight of a carboxamide compound comprising 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenyl-hexanamide or a pharmaceutically acce...

Full description

Saved in:
Bibliographic Details
Main Authors MARCELLIN, Claire, BURROWS, Jane, MAGEE, Gavin
Format Patent
LanguageEnglish
Published 02.02.2023
Subjects
DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY
DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

Abstract Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by weight of a carboxamide compound comprising 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenyl-hexanamide or a pharmaceutically acceptable salt thereof and an excipient. Another powder formulation includes in addition to the carboxamide compound or its hydrochloride salt a long acting β2 adrenoreceptor agonist and an inhalable corticosteroid.
AbstractList Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by weight of a carboxamide compound comprising 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenyl-hexanamide or a pharmaceutically acceptable salt thereof and an excipient. Another powder formulation includes in addition to the carboxamide compound or its hydrochloride salt a long acting β2 adrenoreceptor agonist and an inhalable corticosteroid.
Author BURROWS, Jane
MAGEE, Gavin
MARCELLIN, Claire
Author_xml – fullname: MARCELLIN, Claire
– fullname: BURROWS, Jane
– fullname: MAGEE, Gavin
BookMark eNqNyk0KwjAQQOEsdOHfHQpuLDhgplRwWcTiAXQnlNCMJpBOSptC4-mt4AGEB2_zLcWMPdNCPErfNYNTwXruE8u1G7TlV5LDLvtmou78GFtDPC1Vbwp2AiAhuhRyaCiY6AD3CNp-VXSGRsWqsZrWYv5UrqfN7yuxLS-38xWo9RX1raqJKVTFHQ8o8XRElIXM_lMfKSo88g
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID AU2021296221A1
GroupedDBID EVB
ID FETCH-epo_espacenet_AU2021296221A13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:20:01 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_AU2021296221A13
Notes Application Number: AU20210296221
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230202&DB=EPODOC&CC=AU&NR=2021296221A1
ParticipantIDs epo_espacenet_AU2021296221A1
PublicationCentury 2000
PublicationDate 20230202
PublicationDateYYYYMMDD 2023-02-02
PublicationDate_xml – month: 02
  year: 2023
  text: 20230202
  day: 02
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies Mylan Pharma UK Limited
RelatedCompanies_xml – name: Mylan Pharma UK Limited
Score 3.4457028
Snippet Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by...
SourceID epo
SourceType Open Access Repository
SubjectTerms DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY
DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230202&DB=EPODOC&locale=&CC=AU&NR=2021296221A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS4NQFD6MFdVbraLVikEhDbqkV93sYcTmD0awH8QWewiGer1MMDfSEf73nXtxtaeBqHgvFz3w-Z2j3zkH4AFJW-OUaUSPDJUYTO8Qn774xER2RgLhzJBFkoaj9mBmvM3NeQWSbS6MrBP6I4sjIqJCxHsu39fr_49YjtRWZs9BjJdWr9606yhldIz-NO4Up991J2NnbCu2jZGkMnoXY8hsbUq1HsZKB-hIdwQe3I--yEtZ75KKdwqHE1wvzc-gEqU1OLa3vddqcDQsf3njaYm-7Bw-PXQwy3ZbWTNOw2QjmKdpkkddbMuCCVGKUG3hoSVkPDFOwPCtSFrEJKJbdJEQ-kQJi8WsIlmK9Bb_Cy1xAfeeO7UHBG9z8WeVRW-2-0z6JVTTVRpdQTNg3FK5zwKLW4avqgFHp8IwEcg80ENLrUNj30rX-4dv4ETYWQqXaQOq-fcmukVezoM7ac5fwsOQMw
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS4NQFD6MFa23WkU_Vg0KadAld9XNHkZsOlm1X8QWexiI7nqZYG40R_jfd-7F1Z4GouK9XPTA53eOfuccgHsk7SqnrEq0QFeJzrQ68eizRwxkZyQQznRZJKnXr3XG-tvEmOQg2uTCyDqhP7I4IiJqhnhP5Pt6-f8Ry5baytWTH-KlxYszathKFh2jP407xW412sOBPbAUy8JIUul_iDFkthql1SbGSnvoZNcFHtqfLZGXstwmFecI9oe4XpwcQy6Ii1CwNr3XinDQy35542mGvtUJTB10MLN2W6tyGM-itWCeskEeNLHNUyZEKUK1hYeKkPGEOAHDtzSqEIOIbtFpROgjJSwUs9JoLtJbvC-0xCncOe2R1SF4m-6fVdzmePuZtDPIx4s4OIeyz7ipco_5Jjd1T1V9jk6FbiCQua_NTPUCSrtWutw9fAuFzqjXdbuv_fcrOBQ2lyJmWoJ88r0OrpGjE_9GmvYXsyGTJg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Formulations+including+5-%283-%283-hydroxyphenoxy%29azetidin-1-yl%29-5-methyl-2%2C2-diphenylhexanamide&rft.inventor=MARCELLIN%2C+Claire&rft.inventor=BURROWS%2C+Jane&rft.inventor=MAGEE%2C+Gavin&rft.date=2023-02-02&rft.externalDBID=A1&rft.externalDocID=AU2021296221A1